Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AYLA

Ayala Pharmaceuticals (AYLA) Stock Price, News & Analysis

Ayala Pharmaceuticals logo

About Ayala Pharmaceuticals Stock (NASDAQ:AYLA)

Advanced Chart

Key Stats

Today's Range
$0.50
$0.50
50-Day Range
$0.38
$0.58
52-Week Range
$0.36
$7.31
Volume
N/A
Average Volume
76,300 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive AYLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AYLA Stock News Headlines

OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
OS Therapies Expands Pipeline With Ayala Asset Acquisition, Stock Up
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
ADXS Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals (ADXS) Earnings Dates & Reports
Advaxis, Inc.: Advaxis and Ayala Pharmaceuticals Complete Merger
See More Headlines

AYLA Stock Analysis - Frequently Asked Questions

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) posted its earnings results on Monday, November, 15th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.12. The firm earned $0.63 million during the quarter, compared to analyst estimates of $0.82 million. Ayala Pharmaceuticals had a negative net margin of 2,341.69% and a negative trailing twelve-month return on equity of 182.13%.

Ayala Pharmaceuticals (AYLA) raised $50 million in an initial public offering (IPO) on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include HubSpot (HUBS), Netflix (NFLX), ForgeRock (FORG), Bank of America (BAC), ConocoPhillips (COP) and Diamondback Energy (FANG).

Company Calendar

Last Earnings
11/15/2021
Today
7/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AYLA
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.25 million
Net Margins
-2,341.69%
Pretax Margin
-2,298.60%

Debt

Sales & Book Value

Annual Sales
$3.51 million
Price / Cash Flow
N/A
Book Value
$2.45 per share
Price / Book
0.21

Miscellaneous

Free Float
14,287,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
1.98
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:AYLA) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners